

Bing-He Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2506768/publications.pdf>

Version: 2024-02-01

100
papers

4,408
citations

236833

25
h-index

114418

63
g-index

111
all docs

111
docs citations

111
times ranked

6270
citing authors

#	ARTICLE	IF	CITATIONS
1	Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China. <i>Breast</i> , 2022, 61, 129-135.	0.9	3
2	The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 707-716.	1.0	8
3	Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial. <i>Cancer Research</i> , 2022, 82, PD10-05-PD10-05.	0.4	4
4	Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER2-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. <i>Cancer Medicine</i> , 2022, , .	1.3	8
5	Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. <i>International Journal of Cancer</i> , 2022, 151, 578-589.	2.3	6
6	Development and External Validation of a Clinical Nomogram for Individually Predicting Survival of Metaplastic Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e798-e806.	1.1	2
7	Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis. <i>Clinical Breast Cancer</i> , 2021, 21, e497-e505.	1.1	10
8	Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1368-1375.	2.8	10
9	Profile and outcome of receptor conversion in breast cancer metastases: a nationwide multicenter epidemiological study. <i>International Journal of Cancer</i> , 2021, 148, 692-701.	2.3	11
10	Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2 ⁻) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials. <i>Frontiers of Medicine</i> , 2021, 15, 208-220.	1.5	8
11	Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. <i>Clinical Breast Cancer</i> , 2021, 21, 191-198.	1.1	2
12	Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 71-79.	1.1	11
13	Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 135-150.	1.0	3
14	Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 345-353.	0.6	1
15	Impact of coronavirus disease 2019 on the clinical diagnosis and treatment of breast cancer in China. <i>Chinese Medical Journal</i> , 2021, 134, 590-592.	0.9	0
16	CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?. <i>Lancet Oncology</i> , The, 2021, 22, 159-160.	5.1	10
17	Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy. <i>BMC Cancer</i> , 2021, 21, 341.	1.1	3
18	A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA1 mutation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1087-1087.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	2
20	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	7.1	19
21	Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nationwide multicenter study. <i>Cancer Medicine</i> , 2021, 10, 6744-6761.	1.3	5
22	Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	1
23	Clinicopathological Characteristics and Prognosis of Squamous Cell Carcinoma of the Breast: A Population-Based Analysis. <i>Cancer Control</i> , 2021, 28, 107327482110443.	0.7	3
24	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1359-1368.	2.3	55
25	Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis. <i>Cancer Communications</i> , 2020, 40, 738-742.	3.7	3
26	Clinical development of immuno-oncology in China. <i>Lancet Oncology</i> , The, 2020, 21, 1013-1016.	5.1	16
27	Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. <i>Breast</i> , 2020, 54, 114-120.	0.9	26
28	Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 59.	2.3	32
29	Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. <i>Cancer Communications</i> , 2020, 40, 260-269.	3.7	18
30	Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 67-77.	1.1	24
31	Anticancer drug R&D landscape in China. <i>Journal of Hematology and Oncology</i> , 2020, 13, 51.	6.9	6
32	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 689-697.	1.1	25
33	Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. <i>International Journal of Cancer</i> , 2020, 147, 3490-3499.	2.3	11
34	Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1774-1784.	0.8	64
35	Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. <i>Frontiers in Oncology</i> , 2020, 10, 599604.	1.3	2
36	Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100606.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Availability of anticancer biosimilars in 40 countries. <i>Lancet Oncology</i> , The, 2020, 21, 197-201.	5.1	13
38	[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1106-TPS1106.	0.8	4
39	A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1109-TPS1109.	0.8	9
40	Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS599-TPS599.	0.8	6
41	A prospective, open-label, multicenter, phase IV clinical study on the safety and efficacy of lobaplatin in the treatment of metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13062-e13062.	0.8	0
42	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73
43	Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2610-2619.	0.8	226
44	Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	1.3	51
45	A novel analysis method for biomarker identification based on horizontal relationship: identifying potential biomarkers from large-scale hepatocellular carcinoma metabolomics data. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 6377-6386.	1.9	13
46	Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. <i>Lancet Oncology</i> , The, 2019, 20, e619-e626.	5.1	63
47	Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. <i>Cancer Biology and Medicine</i> , 2019, 16, 173.	1.4	47
48	<p>Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4699-4706.	0.9	14
49	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5212-5220.	3.2	60
50	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	1.1	26
51	Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 963-974.	1.1	8
52	Association between tooth loss and upper gastrointestinal cancer: A 30-year follow-up of the Linxian Dysplasia Nutrition Intervention Trial Cohort. <i>Thoracic Cancer</i> , 2019, 10, 966-974.	0.8	18
53	Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. <i>European Journal of Cancer</i> , 2019, 112, 57-65.	1.3	56
54	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37-298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	6.3	260

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 866-872.	0.7	4
56	Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. <i>Thoracic Cancer</i> , 2018, 9, 613-620.	0.8	0
57	Phase I safety and pharmacokinetic study of ciptinib, an original dual tyrosine kinase inhibitor. <i>Thoracic Cancer</i> , 2018, 9, 1041-1047.	0.8	1
58	Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 327-339.	0.7	3
59	The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis. <i>Scientific Reports</i> , 2017, 7, 42045.	1.6	41
60	Association between oral leukoplakia and risk of upper gastrointestinal cancer death: A follow-up study of the Linxian General Population Trial. <i>Thoracic Cancer</i> , 2017, 8, 642-648.	0.8	9
61	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. <i>Scientific Reports</i> , 2017, 7, 5995.	1.6	25
62	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3105-3112.	0.8	168
63	Assessing tumor heterogeneity using circulating tumor DNA to predict and monitor therapeutic response in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11543-11543.	0.8	2
64	Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 502-502.	0.8	22
65	Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 512-512.	0.8	8
66	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA4-LBA4.	0.8	4
67	OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA4-LBA4.	0.8	28
68	Relationship between Topoisomerase II Alpha Overexpression and Prognosis in Chinese Gastric Cancer Patients. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2017, 36, 207-216.	0.6	2
69	Treatment patterns and patient profiles for docetaxel-based adjuvant chemotherapy in early-stage breast cancer in China: A pooled analysis of four observational studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12017-e12017.	0.8	0
70	Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 39.	4.9	9
71	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	5.1	125
72	Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. <i>Oncotarget</i> , 2016, 7, 60647-60656.	0.8	63

#	ARTICLE	IF	CITATIONS
73	Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study. <i>Oncotarget</i> , 2016, 7, 50643-50655.	0.8	10
74	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
75	Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 436-446.	5.1	232
76	A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes. <i>Cancer Biology and Therapy</i> , 2015, 16, 1746-1753.	1.5	20
77	A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2+ metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11596-e11596.	0.8	4
78	Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs. <i>Anti-Cancer Drugs</i> , 2014, 25, 1089-1094.	0.7	8
79	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2—Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	0.8	118
80	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology</i> , 2014, 15, 1137-1146.	5.1	382
81	Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxane-epirubicin in patients with locally advanced triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1105-1105.	0.8	2
82	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA4-LBA4.	0.8	32
83	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA4-LBA4.	0.8	51
84	Phase II clinical studies of UTD1, an epothilone analog, in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1040-1040.	0.8	27
85	Survival with docetaxel plus capecitabine comparing with vinorelbine plus capecitabine followed by capecitabine maintenance treatment as first-line therapy in patients with advanced breast cancer: A phase III randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1049-1049.	0.8	0
86	Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1042-1042.	0.8	0
87	Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2013, 33, 262-265.	1.0	7
88	Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1087-1087.	0.8	1
89	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. <i>Journal of Clinical Oncology</i> , 2013, 31, 505-505.	0.8	34
90	A first-in-human phase I study of ER-136 modifier icaritin in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2614-2614.	0.8	0

#	ARTICLE	IF	CITATIONS
91	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS649-TPS649.	0.8	11
92	A phase III, randomized trial of docetaxel plus carboplatin (TP) versus epirubicin plus cyclophosphamide followed by docetaxel (EC-T) as adjuvant treatment for triple-negative, early-stage breast cancer in Chinese patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1135-TPS1135.	0.8	1
93	Patterns of docetaxel application in breast cancer patients from China: Experience in 42 cancer centers.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11537-e11537.	0.8	0
94	Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline and taxen-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11025-e11025.	0.8	0
95	Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study. <i>Chinese Medical Journal</i> , 2012, 125, 764-9.	0.9	2
96	Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. <i>Chinese Journal of Cancer</i> , 2011, 30, 327-335.	4.9	38
97	A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 320-329.	0.7	6
98	Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. <i>Lung Cancer</i> , 2009, 66, 114-119.	0.9	65
99	Epothilones in the treatment of breast cancer: Review of clinical experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, S30.	0.7	2
100	Clinicopathological characteristics and prognosis of microinvasive breast cancer: A populationâ€based analysis. <i>Cancer Medicine</i> , 0, , .	1.3	3